Under a tenth of people who could benefit from obesity jabs like Wegovy have access to them, states the World Health Organization as it releases its first recommendations on the drugs.
With in excess of 1,000,000,000 people worldwide now classified as obese, it is calling for increased and just availability to GLP-1 medication.
According to forecasts, more than two billion could be living with obesity by 2030 unless action is taken.
"The latest guidelines recognises that excess weight is a lifelong illness that can be managed with holistic and ongoing support," said WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are major hurdles to widespread availability to the treatments that can help people shift considerable weight, explains the agency.
Weight-Loss Drug Shortage
Even in the present most optimistic case, the manufacturing of these medications would only suffice for about 100 million people – under 10% of the global need, as stated by the WHO.
The recommendation urges governments and firms to increase availability, via approaches including licensing agreements.
Exclusive production rights on semaglutide – the main ingredient of the drug Wegovy – is scheduled to end in multiple nations in 2026.
The Way Obesity Injections Function
GLP-1 drugs imitate a natural hormone to delay gastric emptying, suppress the appetite and boost satiety so individuals consume fewer calories.
Patients usually see weight reduction after several weeks of beginning the weekly injections.
Evidence suggests people may see weight return after a year of stopping the drug, as their normal hunger return.
To be carrying excess weight raises your likelihood for contracting health problems, such as diabetes, heart disease, stroke, and some malignancies.
Obesity affects people in every country and was associated with 3.7 million fatalities worldwide in 2024, according to the WHO.
